Advances in IVF Technology in Georgia: Current Status of PGT and Vitrification

Current Status of IVF Technology in Georgia: Substantive Progress in Three Areas

In recent years, the development of assisted reproductive technology in Georgia has not been merely rhetorical but has focused on three verifiable technical areas: embryo genetic testing (PGT-A/PGT-M), the large-scale application of vitrification, and the systematic upgrade of embryo laboratory culture systems. Progress in these three areas directly impacts clinical pregnancy rates, embryo utilization rates, and per-cycle efficiency for patients.

Embryo Genetic Testing: Clinical Coverage of PGT-A and PGT-M

Major fertility centers in Georgia currently offer PGT-A (aneuploidy screening) and PGT-M (monogenic disease detection) services. PGT-A utilizes a next-generation sequencing (NGS) platform, covering structural and numerical abnormalities of all 23 pairs of chromosomes. Technically, after embryos are cultured to the blastocyst stage on days 5-6, 3-5 trophectoderm cells are biopsied, with the testing cycle taking approximately 10-14 working days.

The implementation of PGT-M depends on whether the fertility center collaborates with a laboratory capable of genetic counseling. Local laboratories in Georgia started later in monogenic disease detection; some centers send samples to partner laboratories in Europe for testing, extending the cycle to 3-4 weeks.

Regarding suitable populations, PGT-A is appropriate for women aged 38 and above, those with recurrent implantation failure, previous pregnancies with chromosomal abnormalities, or recurrent miscarriage. PGT-M is suitable for families known to carry monogenic pathogenic mutations or with a history of genetic diseases. Unsuitable situations include a low number of embryos (fewer than 3 blastocysts), or low-risk couples with normal chromosomes and age <35, where PGT does not improve live birth rates.

Vitrification: Key Indicator of Survival Rate

Fertility centers in Georgia have fully adopted vitrification for oocyte and embryo cryopreservation, replacing the earlier slow programmable freezing. Vitrification uses an ultra-high cooling rate (>15,000°C/min) to transform cellular contents into a glassy state, preventing ice crystal formation and physical damage to the cytoskeleton and organelles.

Clinical data show that centers in Georgia with mature vitrification protocols achieve blastocyst freeze-thaw survival rates of 93%-97% and oocyte survival rates of approximately 85%-92%. There is no significant difference in survival rates for cryopreservation periods within 5 years; data for samples exceeding 10 years are limited, and long-term follow-up conclusions are lacking.

Clinical pregnancy rates from frozen embryo transfers can approach or equal those of fresh cycle transfers, provided endometrial receptivity is optimally prepared. Live birth rates from frozen oocytes are significantly influenced by oocyte quality, and cryopreservation is recommended before age 35.

Physician's Perspective: Technical Maturity and Clinical Decision Logic

As a reproductive physician, determining whether a technology is mature relies not on promotional claims but on three indicators: clinical pregnancy rate, multi-center reproducibility, and complication control levels.

In clinical decision-making, I advise patients to choose a combination of technologies based on their age, ovarian reserve function, and previous treatment history. For example, patients with normal ovarian reserve, age <35, and no genetic history can achieve ideal pregnancy rates with conventional IVF or ICSI without unnecessarily adding PGT. For older patients or those with diminished ovarian reserve, the rate of embryonic chromosomal aneuploidy is significantly higher, and the benefit of PGT-A is clear.

Technical Differences and Selection Strategies by Age Group

Age is the most critical variable affecting the application of IVF technology in Georgia. The technical needs and degree of benefit differ significantly among patients of different ages.

Age 35 and Under

In this age group, the incidence of chromosomal aneuploidy is approximately 20-30%, and live birth rates from natural conception and IVF are relatively high. The technical focus is on choosing an ovarian stimulation protocol to avoid Ovarian Hyperstimulation Syndrome and ensuring the stability of blastocyst culture. PGT-A is not routinely recommended for this age group unless there is a history of recurrent miscarriage or chromosomal abnormalities in previous pregnancies.

Ages 36-40

The aneuploidy rate rises to 40-50%, and the benefit of PGT-A becomes apparent. Fertility centers in Georgia typically recommend blastocyst culture plus PGT-A for this age group to select euploid embryos for transfer, thereby reducing miscarriage rates. Additionally, the maturity of vitrification makes frozen embryo transfer protocols more flexible, avoiding the impact of high progesterone levels in fresh cycles on endometrial receptivity.

Age 41 and Above

The aneuploidy rate exceeds 70%, maximizing the value of PGT-A, but this group also faces the challenge of insufficient embryo numbers. Patients in this age group have fewer oocytes retrieved per cycle and a lower rate of blastocyst formation, potentially resulting in no euploid embryos available for transfer. Some centers in Georgia recommend ovarian function assessment (AMH, antral follicle count) and pretreatment before ovarian stimulation to try to obtain an adequate number of oocytes.

Technical Differences Between Georgia and Other Countries

Comparing IVF technology in Georgia with countries like Ukraine, Greece, and Spain, the differences are mainly in three aspects:

• Technical Access Restrictions: Georgian law permits PGT for chromosomal screening and some monogenic disease detection but does not allow advanced techniques like mitochondrial replacement. Spain and Greece lead Georgia in the breadth and depth of genetic testing.
• Laboratory Hardware Level: The equipment (incubators, air quality systems, micromanipulators) in top-tier Georgian fertility centers is comparable to mainstream European centers, but hardware updates in small and medium-sized centers are slower, leading to greater inter-laboratory variability than in Europe. When choosing, request to see laboratory quality control records and recent pregnancy data.
• Technical Operation Experience: The average annual number of cycles performed by embryology teams in Georgian centers is lower than in top centers in Spain and Greece, which can affect the stability of biopsy success rates and freeze-thaw survival rates. It is advisable to inquire in detail about the embryology team's years of experience and annual workload.

Technical Steps in the Actual Process

The complete technical process of IVF in Georgia includes the following key steps, each with corresponding technical parameters and quality control standards.

Ovarian Stimulation Phase

Antagonist protocols or PPOS protocols are primarily used; some centers use mild stimulation protocols for patients with diminished ovarian reserve. The choice of stimulation drugs (recombinant FSH vs. urinary FSH) and dose adjustments are based on the patient's AMH, FSH, LH, E2 levels, and antral follicle count.

Oocyte Retrieval and Assessment

Oocytes are retrieved via transvaginal ultrasound guidance. The rate of mature oocytes (MII stage) is typically 75-85%. Georgian centers generally use existing international standards (e.g., morphological scoring) for oocyte morphology assessment, but advanced techniques like polarized light imaging are not yet widespread.

Fertilization Method

IVF or ICSI is chosen based on male semen parameters. Many centers in Georgia tend to use ICSI even for non-male factor infertility to improve fertilization rates and avoid unexpected fertilization failure. The normal fertilization rate after ICSI is approximately 70-80%.

Embryo Culture and Monitoring

Embryos are cultured in time-lapse incubators until days 5-6. Some centers are equipped with time-lapse imaging systems that record embryonic cleavage dynamics in real-time, aiding in selecting embryos with the highest developmental potential for transfer or cryopreservation. The blastocyst formation rate, influenced by embryo quality, culture media, and conditions, ranges from 50-65% in Georgian centers.

PGT Biopsy and Referral

Trophectoderm cells are biopsied at the blastocyst stage on days 5-6. The biopsied embryos are immediately cryopreserved by vitrification. After receiving the test results, euploid embryos are selected for thawing and transfer. The biopsy process requires high technical skill from the embryologist; improper handling can affect the embryo's continued development after thawing.

Freezing and Thawing

Vitrification is used, employing commercial cryocarriers and cryoprotectant kits. Thawing involves rapid warming, removal of cryoprotectants, and assessment of embryo survival and continued developmental ability. Embryos are typically cultured for about 2 hours after thawing before transfer.

Easily Overlooked Technical Details

When undergoing IVF treatment in Georgia, several technical details are often overlooked by patients:

• Biopsy Timing and Embryo Development Synchrony: Embryos from the same cohort may develop at different rates. Biopsy too early (early blastocyst on day 5) may result in too few cells biopsied or embryo damage; too late (after day 6) may affect the implantation window. The embryologist must individualize the timing based on each embryo's degree of expansion and inner cell mass grade.
• Type of Cryocarrier: Different cryocarriers (e.g., Cryotop, Cryotech, Cryoleaf) have different cooling rates and survival rates. Different centers in Georgia use different carriers; patients can inquire about the specific model.
• Culture Media Batch Quality Control: Variations in production batches of embryo culture media can affect blastocyst formation rates. Reputable centers should have strict culture media quality control records and pre-test data before changing batches.
• Air Filtration System: Laboratory air quality (VOCs, CO₂ concentration, temperature, humidity) directly impacts embryo development. Some older centers in Georgia may have substandard air filtration systems. When choosing, confirm if the lab is equipped with a HEPA + activated carbon filtration system.
• Mosaicism in PGT Results: Embryos may exhibit chromosomal mosaicism. PGT results may not fully reflect the true chromosomal composition of the embryo. In clinical decision-making, embryos with a mosaicism rate below 20% still have some chance of live birth, but there are risks of miscarriage and birth defects, requiring thorough communication.

Practitioner's Observation: Real Bottlenecks in Technological Development

As a practitioner closely following advances in assisted reproductive technology, I believe that while IVF technology in Georgia has made visible progress, it still faces several real bottlenecks:

• Insufficient Local Genetic Talent Pool: Local capacity for PGT-M testing is limited, causing families carrying rare mutations to wait longer, and the depth of genetic counseling is not as profound as in European centers.
• High Laboratory Personnel Turnover: The training period for embryologists is long (typically 3-5 years to operate independently). Some centers in Georgia face the risk of losing key embryologists, which can affect the stability of technical standards.
• Differences in Quality Management Systems: Not all Georgian fertility centers have international quality certifications (e.g., ISO 15189). The uniformity of quality control standards between laboratories needs improvement.
• Lack of Data Transparency: Some centers publish clinical pregnancy rates without stratified statistics (e.g., by age, cycle number, etiology), making it difficult to compare horizontally or make realistic expectations.

Special Situation Management: Boundaries of Technical Application

In the following special situations, the technical capacity in Georgia may face challenges:

• Customized Testing for Rare Genetic Diseases: Designing personalized probes for specific mutations is usually beyond the capacity of local Georgian laboratories, requiring referral to European partner centers, extending the cycle and significantly increasing costs.
• Mitochondrial Diseases: Mitochondrial donation/replacement technology is not yet legalized in Georgia and has no clinical application conditions.
• Recurrent Implantation Failure with Immune Factors: Georgian fertility centers have limited means for reproductive immunological assessment; tests like endometrial immune cell profiling and cytokine analysis are not yet part of routine protocols.
• Ovarian Failure: For patients with ovarian failure, egg donation is the only viable option. While the management of egg donor banks in Georgia is relatively standardized, the genetic screening coverage for donor eggs is lower than in countries like Spain, potentially posing genetic risks.

Criteria for Choosing Technology

When selecting a fertility center and technology plan in Georgia, it is recommended to use the following objective indicators as a basis for judgment:

• Blastocyst Formation Rate: Reflects the overall level of the laboratory culture system; normal range should be 50-65%.
• PGT-A Biopsy Success Rate: The proportion of biopsied embryos successfully amplified and yielding results should be ≥95%.
• Embryo Freeze-Thaw Survival Rate: Reflects the stability of the vitrification technique; should be ≥93%.
• Clinical Pregnancy Rate per Euploid Transfer: Stratified data (by age) is more valuable for reference.
• Laboratory Quality Control Records: Includes culture media batch records, temperature monitoring logs, air quality test reports, etc.
• Embryology Team Stability: Core embryologists' years of experience and annual number of cycles performed.

These indicators are more reliable than success rates in promotional materials. You can directly request the last 12 months of data from the fertility center.

Matching Timeline with Technical Procedures

The timeline for the IVF technical process in Georgia needs to align with various technical steps:

• Initial Consultation and Tests: Complete basic fertility assessment (AMH, FSH, antral follicle count), infectious disease screening, and chromosomal karyotype analysis domestically, taking about 2 weeks.
• Ovarian Stimulation and Egg Retrieval: Cycle takes approximately 10-14 days (from day 2 of menstruation to retrieval day).
• Embryo Culture and PGT Testing: Blastocyst culture for 5-6 days, biopsy and referral, waiting for results for 10-14 working days (PGT-A), PGT-M requires 3-4 weeks.
• Frozen Embryo Transfer: Endometrial preparation in the next menstrual cycle after PGT results are received; transfer day is typically around day 18-22 of the cycle.
• Pregnancy Confirmation: Blood test for hCG 10-12 days after transfer.

A complete cycle (from initial consultation to pregnancy confirmation) usually takes 2.5-3.5 months, with PGT-M testing being the main variable. It is advisable to plan the timeline in advance, allowing buffer time for potential delays in testing.

Impact of Technological Advances on Timeline

The maturity of vitrification has made the "freeze-all embryo + elective transfer" strategy standard. Patients can avoid dual hormonal stimulation of the uterus and ovaries in the same cycle, which is beneficial for improving endometrial receptivity. However, this requires patients to have sufficient patience to complete the衔接 of two cycles and is not suitable for those hoping to complete a transfer within one month.

Risk Reminder: Boundaries of Technical Application

Any assisted reproductive technology has its applicable boundaries and potential risks. PGT testing carries a possibility of false positives and false negatives (approximately 1-2%). Although vitrification is mature, there is still a very low probability of cryo-damage causing embryos to stop developing after thawing. Technological advances in Georgia have improved treatment efficiency but have not changed the fundamental laws of medicine – age is an irreversible factor, ovarian reserve cannot be regenerated, and embryo quality ultimately depends on the genetic integrity of the gametes themselves. Technology can optimize the selection process but cannot create high-quality embryos that do not originally exist.

Suggestions for Next Steps

For patients considering IVF in Georgia, it is recommended to follow these steps: Complete a comprehensive fertility assessment (including chromosomal karyotype analysis and genetic counseling for both partners), clarify your core needs (whether you truly need PGT, egg freezing, or fresh embryo transfer), compare the technical parameters of 2-3 Georgian fertility centers (focusing on blastocyst formation rate, PGT biopsy success rate, freeze-thaw survival rate), request age-stratified pregnancy data for the last 12 months, and confirm the qualifications and stability of the embryology team. Adequate preparation in terms of technology and timeline planning can maximize the practical benefits brought by advances in IVF technology in Georgia.